Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): An open-label, randomised, phase 3 trial

The Lancet Oncology

Volumn 15, Issue 8, 2014, Pages 829-840

  Middleton, Gary ^a   Silcocks, Paul ^b   Cox, Trevor ^b   Valle, Juan ^c   Wadsley, Jonathan ^d   Propper, David ^e   Coxon, Fareeda ^f   Ross, Paul ^g   Madhusudan, Srinivasan ^h   Roques, Tom ⁱ   Cunningham, David ^j   Falk, Stephen ^k   Wadd, Nick ^l   Harrison, Mark ^m   Corrie, Pippa ⁿ   Iveson, Tim ^o   Robinson, Angus ^p   McAdam, Karen ^q   Eatock, Martin ^r   Evans, Jeff ^s   Archer, Caroline ^t   Hickish, Tamas ^u   Garcia Alonso, Angel ^v   Nicolson, Marianne ^w   Steward, William ^x   Anthoney, Alan ^y   Greenhalf, William ^b   Shaw, Victoria ^b   Costello, Eithne ^b   Naisbitt, Dean ^b   Rawcliffe, Charlotte ^b   Nanson, Gemma ^b   Neoptolemos, John ^b   more..

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c CHRISTIE HOSPITAL   (United Kingdom)

^d WESTON PARK HOSPITAL   (United Kingdom)

^e ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^f FREEMAN HOSPITAL   (United Kingdom)

^g GUY S HOSPITAL   (United Kingdom)

^h NOTTINGHAM CITY HOSPITAL   (United Kingdom)

ⁱ NORFOLK AND NORWICH UNIVERSITY HOSPITAL   (United Kingdom)

^j INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^k BRISTOL HAEMATOLOGY AND ONCOLOGY CENTRE   (United Kingdom)

^l JAMES COOK UNIVERSITY HOSPITAL   (United Kingdom)

^m MOUNT VERNON HOSPITAL   (United Kingdom)

ⁿ ADDENBROOKE S HOSPITAL   (United Kingdom)

^o SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^p East Sussex Healthcare NHS Trust   (United Kingdom)

^q PETERBOROUGH CITY HOSPITAL   (United Kingdom)

^r BELFAST CITY HOSPITAL   (United Kingdom)

^s UNIVERSITY OF GLASGOW   (United Kingdom)

^t QUEEN ALEXANDRA HOSPITAL   (United Kingdom)

^u POOLE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^v GLAN CLWYD HOSPITAL   (United Kingdom)

^w ABERDEEN ROYAL INFIRMARY   (United Kingdom)

^x LEICESTER ROYAL INFIRMARY   (United Kingdom)

^y ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BILIRUBIN; CAPECITABINE; GEMCITABINE; HEMOGLOBIN; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; TERTOMOTIDE;

ADULT; ADVANCED CANCER; AGED; ANOREXIA; ARTICLE; ASCITES; BILIRUBIN BLOOD LEVEL; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CARDIOPULMONARY ARREST; CLINICAL PROTOCOL; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DIGESTIVE SYSTEM ULCER; DISEASE SEVERITY; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; EDEMA; EMBOLISM; FAINTNESS; FATIGUE; FEMALE; FEVER; GASTROINTESTINAL DISEASE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL OBSTRUCTION; HAND FOOT SYNDROME; HEART ARRHYTHMIA; HEART DISEASE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERCALCEMIA; HYPOTENSION; IMMUNOMODULATION; INFECTION; INJECTION SITE REACTION; KIDNEY FAILURE; LIVER DYSFUNCTION; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MOOD DISORDER; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPHIL COUNT; NEUTROPHILIA; OVERALL SURVIVAL; PAIN; PANCREAS ADENOCARCINOMA; PANCREAS METASTASIS; PANCREATITIS; PHASE 3 CLINICAL TRIAL; PLEURA EFFUSION; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RASH; SOMNOLENCE; THROMBOCYTE COUNT; THROMBOSIS; THROMBUS; URINE RETENTION; VOMITING;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CANCER VACCINES; CELL PROLIFERATION; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FATIGUE; FEMALE; FLUOROURACIL; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNOLOGIC FACTORS; INTENTION TO TREAT ANALYSIS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEUTROPENIA; PAIN; PANCREATIC DUCTS; PANCREATIC NEOPLASMS; PEPTIDE FRAGMENTS; T-LYMPHOCYTES; TELOMERASE;

EID: 84903527674     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(14)70236-0     Document Type: Article

References (38)

1. Van Laethem JL, Verslype C, Iovanna JL, et al. New strategies and designs in pancreatic cancer research: consensus guidelines report from a European expert panel. Ann Oncol 2012, 23:570-576.
2. Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011, 364:1817-1825.
3. Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013, 369:1691-1703.
4. Hammel P, Huguet F, Van Laethem J-L, et al. Comparison of chemoradiotherapy (CRT) and chemotherapy (CT) in patients with a locally advanced pancreatic cancer (LAPC) controlled after 4 months of gemcitabine with or without erlotinib: final results of the international phase III LAP 07 study. Proc Am Soc Clin Oncol 2013, 31(suppl). abstr LBA4003.
5. Schlom J Therapeutic cancer vaccines: current status and moving forward. J Natl Cancer Inst 2012, 104:599-613.
6. Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013, 369:122-133.
7. Günes C, Rudolph KL The role of telomeres in stem cells and cancer. Cell 2013, 152:390-393.
8. Mocellin S, Pooley KA, Nitti D Telomerase and the search for the end of cancer. Trends Mol Med 2013, 19:125-133.
9. Hiyama E, Kodama T, Shinbara K, et al. Telomerase activity is detected in pancreatic cancer but not in benign tumors. Cancer Res 1997, 57:326-331.
10. Bernhardt SL, Gjertsen MK, Trachsel S, et al. Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: a dose escalating phase I/II study. Br J Cancer 2006, 95:1474-1482.
11. Brunsvig PF, Aamdal S, Gjertsen MK, et al. Telomerase peptide vaccination: a phase I/II study in patients with non-small cell lung cancer. Cancer Immunol Immunother 2006, 55:1553-1564.
12. Kokhaei P, Palma M, Hansson L, Osterborg A, Mellstedt H, Choudhury A Telomerase (hTERT 611-626) serves as a tumor antigen in B-cell chronic lymphocytic leukemia and generates spontaneously antileukemic, cytotoxic T cells. Exp Hematol 2007, 35:297-304.
13. Inderberg-Suso EM, Trachsel S, Lislerud K, Rasmussen AM, Gaudernack G Widespread CD4+ T-cell reactivity to novel hTERT epitopes following vaccination of cancer patients with a single hTERT peptide GV1001. Oncoimmunology 2012, 1:670-686.
14. Nowak AK, Lake RA, Marzo AL, et al. Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells. J Immunol 2003, 170:4905-4913.
15. Fridlender ZG, Sun J, Singhal S, et al. Chemotherapy delivered after viral immunogene therapy augments antitumor efficacy via multiple immune-mediated mechanisms. Mol Ther 2010, 18:1947-1959.
16. Liu WM, Fowler DW, Smith P, Dalgleish AG Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses. Br J Cancer 2010, 102:115-123.
17. Suzuki E, Kapoor V, Jassar AS, Kaiser LR, Albelda SM Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin Cancer Res 2005, 11:6713-6721.
18. Vincent J, Mignot G, Chalmin F, et al. 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res 2010, 70:3052-3061.
19. Rettig L, Seidenberg S, Parvanova I, et al. Gemcitabine depletes regulatory T-cells in human and mice and enhances triggering of vaccine-specific cytotoxic T-cells. Int J Cancer 2011, 129:832-838.
20. Galetto A, Buttiglieri S, Forno S, Moro F, Mussa A, Matera L Drug- and cell-mediated antitumor cytotoxicities modulate cross-presentation of tumor antigens by myeloid dendritic cells. Anticancer Drugs 2003, 14:833-843.
21. Nowak AK, Robinson BW, Lake RA Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors. Cancer Res 2003, 63:4490-4496.
22. Cunningham D, Chau I, Stocken DD, et al. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol 2009, 27:5513-5518.
23. Ji Q, Gondek D, Hurwitz AA Provision of granulocyte-macrophage colony-stimulating factor converts an autoimmune response to a self-antigen into an antitumor response. J Immunol 2005, 175:1456-1463.
24. Sultana A, Smith CT, Cunningham D, Starling N, Neoptolemos JP, Ghaneh P Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer. J Clin Oncol 2007, 25:2607-2615.
25. Sultana A, Smith CT, Cunningham D, Starling N, Tait D, Neoptolemos JP, Ghaneh P Meta-analyses on the management of locally advanced pancreatic cancer using radiation/combined modality therapy. Br J Cancer 2007, 96:1183-1190.
26. Shaw VE, Naisbitt DJ, Costello E, Greenhalf W, Park BK, Neoptolemos JP, Middleton GW Current status of GV1001 and other telomerase vaccination strategies in the treatment of cancer. Expert Rev Vaccines 2010, 9:1007-1016.
27. Provenzano PP, Cuevas C, Chang AE, Goel VK, Von Hoff DD, Hingorani SR Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell 2012, 21:418-429.
28. Beatty GL, Chiorean EG, Fishman MP, et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 2011, 33:1612-1616.
29. Feig C, Jones JO, Kraman M, et al. Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proc Natl Acad Sci USA 2013, 110:20212-20217.
30. Tuveson DA, Neoptolemos JP Understanding metastasis in pancreatic cancer: a call for new clinical approaches. Cell 2012, 148:21-23.
31. Kantoff PW, Schuetz TJ, Blumenstein BA, et al. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Onc 2010, 28:1099-1105.
32. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010, 363:411-422.
33. Le DT, Lutz E, Uram JN, et al. Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer. J Immunother 2013, 36:382-389.
34. Slingluff CL, Petroni GR, Olson WC, et al. Effect of granulocyte/macrophage colony-stimulating factor on circulating CD8+ and CD4+ T-cell responses to a multipeptide melanoma vaccine: outcome of a multicenter randomized trial. Clin Cancer Res 2009, 15:7036-7044.
35. Annels NE, Shaw VE, Gabitass RF, et al. The effects of gemcitabine and capecitabine combination chemotherapy and of low dose adjuvant GM-CSF on the levels of myeloid derived suppressor cells in patients with advanced pancreatic cancer. Cancer Immunol Immunother 2014, 63:175-178.
36. Valle JW, Palmer D, Jackson R, et al. Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 study. J Clin Oncol 2014, 32:504-512.
37. Ruden M, Puri N Novel anticancer therapeutics targeting telomerase. Cancer Treat Rev 2013, 39:444-456.
38. Williams SC No end in sight for telomerase-targeted cancer drugs. Nat Med 2013, 19:6.